Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care.
Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 85 Songdokwahak-Ro Yeonsu-Gu, Posco Green Building (Bldg 511),korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://zymedi.com
- HQ
- Incheon, - None -
Zymedi Questions
Zymedi's website is https://zymedi.com
Zymedi's LinkedIn profile is https://kr.linkedin.com/company/zymedi
Zymedi has
11 employees.
View email and phone details for 11
employees at Zymedi.
Zymedi's industry is
Pharmaceutical Manufacturing
Zymedi's categories are Pharmaceutical Manufacturing
Zymedi's founding year is 2019
